This podcast delves into the effects of Ozempic and Wegovy, weight-loss medications originally designed for diabetes, on the obesity crisis in Britain. Produced by Novo Nordisk, these drugs have surged in popularity due to their impressive weight-loss results, resulting in shortages and raising ethical questions about their off-label use. Although the NHS has started prescribing Wegovy for weight loss in specific situations, experts caution that these medications are not quick fixes; they require accompanying lifestyle changes for lasting results. The conversation also highlights Novo Nordisk's fascinating history and examines the wider societal issues contributing to the obesity epidemic in Britain.
Sign in to continue reading, translating and more.
Continue